Pseudohypotension in a Patient with Malignant Hypertension

Ronen Jaffe MD, David A Halon MBChB, Giora Weisz MD, and Basil S Lewis MD

Department of Cardiology, Lady Davis Carmel Medical Center, and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

Key words: pseudohypotension, malignant hypertension, shock

Pseudohypotension is a syndrome in which indirect blood pressure measurement by sphygmomanometer overestimates true intraarterial blood pressure, due to arterial medial sclerosis and calcification [1]. In pseudohypotension, non-invasive measurement of the peripheral blood pressure underestimates true central pressure due to obstructive arterial disease. We report a case in which malignant hypertension was masked by pseudohypotension.

Case Description

A 46-year-old man was referred to the emergency room because of severe generalized weakness and confusion that had intensified during the previous several hours. The patient was a heavy smoker and suffered from chronic obstructive lung disease, non-insulin-dependent diabetes mellitus, coronary artery disease, peripheral vascular disease, and end-stage renal disease necessitating regular hemodialysis. His regular medications included metformin, glibenclamide, bisoprolol, aspirin, furosemide and erythropoietin.

On examination the patient was somnolent, afebrile and not in respiratory distress. The heart rate was 30 beats/minute, and a weak arterial pulse could be palpated over the dialysis shunt in the right antecubital fossa, the left brachial artery and over both femoral arteries. The peripheral pulses were absent and the extremities were cold and cyanotic. Blood pressure in the left arm was 60 mm Hg, without pulsus paradoxus. Blood pressure in the right arm was not measured with a sphygmomanometer to avoid damage to the shunt. Bruits were heard over both carotid and femoral arteries. The jugular venous pulse was elevated 8 cm above the sternal angle, inspiratory crackles could be heard over both lung bases, and the heart sounds were distant. The examination, including a neurological assessment, was otherwise unremarkable.

The electrocardiogram showed a nodal rhythm of 30 beats/minute and left ventricular hypertrophy. The chest X-ray revealed some prominence of interstitial markings. The serum sodium was 139 mmol/L, potassium 5.6 mmol/L, glucose 95 mg/dl (5.3 mmol/L), blood urea nitrogen 50 mg/dl (17.7 mmol/L), creatinine 2 mg/dl (177 µmol/L), carbon dioxide 20 mmol/L, arterial pH 7.36, arterial pO₂ 80 mmHg, and hematocrit 35%. A pulmonary ventilation/perfusion scan revealed no segmental perfusion defects.

The patient was treated with intravenous fluids, atropine, dopamine and norepinephrine. He became unresponsive to verbal commands. The pulse could no longer be palpated in the left arm, but was felt weakly over the shunt. Echocardiography revealed a left ventricle with normal size and function. The right ventricle was enlarged with severe tricuspid regurgitation. A small pericardial effusion was demonstrated without evidence of tamponade. A balloon flotation catheter revealed a systolic blood pressure of 100 mm Hg in the right ventricle and pulmonary artery. The pulmonary capillary wedge pressure was 20 mmHg. An arterial line inserted into the femoral artery revealed a systemic blood pressure of 300/100 mmHg. The cardiac output estimated according to the Fick method was 1.5 L/min.

Vasopressor therapy was stopped and the intraarterial blood pressure gradually decreased to 200/70 mm Hg.
The patient’s complaints and physical findings produced a clinical picture indistinguishable from shock. The patient was mistakenly diagnosed as hypotensive because the blood pressure measured in the left arm did not reflect his systemic blood pressure. Treatment with vasoconstrictors worsened the central hypertension and peripheral hypoperfusion, and caused further neurological deterioration.

The invasive hemodynamic study revealed the correct diagnosis of malignant hypertension [2]. Severe arterial occlusive disease can result from a number of causes, such as Takayasu’s arteritis [3], and is associated with hypertension. In view of the patient’s risk factors, it is likely that his condition was caused by cardiovascular atherosclerosis. The patient probably had chronic unrecognized hypertension, perhaps due to renovascular stenosis. The etiology of the bradycardia was not discovered, and a permanent dual-chamber cardiac pacemaker was later implanted after hemodynamic studies demonstrated a doubling of the cardiac output during temporary pacing.

The entity of pseudohypotension is probably under-recognized and should be kept in mind when evaluating the hemodynamic status of patients at risk for occlusive arterial disease.

References

Correspondence: Dr. R. Jaffe, Dept. of Cardiology, Lady Davis Carmel Medical Center, 7 Michal St., Haifa 34362, Israel. Tel: (972-4) 825 0457; Fax: (972-4) 834 3755; email: jafferonen@hotmail.com.

Pedal Edema Associated with Clozapine Use

Rimona Durst MD1, Sergey Raskin MD1, Gregory Katz MD1, Josef Zislin1 and Ronen Durst MD2

1The Jerusalem Mental Health Center, Kfar Shaul Hospital (affiliated with Hebrew University Hadassah Medical School) and 2Department of Internal Medicine, Hadassah University Hospital, Jerusalem, Israel

Key words: clozapine, side effects, pedal edema

Clozapine, widely recognized as an efficient agent for treating non-remittent schizophrenic patients, is associated with well-established adverse effects such as sedation, weight gain, salivary, palpitations, seizures, and agranulocytosis. We report a case in which an additional possible negative side effect of clozapine was observed, namely pedal edema.

Case Description
This 24-year-old patient was known to suffer from schizophrenia for 6 years. Previous treatment by a variety of neuroleptics (including mood stabilizers) failed to produce long-term amelioration. In view of her frequent relapses, it was decided to initiate clozapine treatment as a sole anti-psychotic agent while maintaining her long-term valproic acid treatment. Clozapine was gradually increased to 400 mg/day with satisfactory results. However, 6 weeks after the commencement, the patient began to show signs of pedal edema and peri-orbital puffiness. No polydipsia was apparent. Physical examination revealed no other abnormal signs. Albumin blood level, and thyroid and liver function tests indicated normal levels. No proteinuria was detected. Other laboratory tests including electrolytes yielded normal results, except for eosinophilia. Echocardiogram showed normal systolic and diastolic functions.

In view of the apparent association between the development of the edema and the initiation of clozapine, the clozapine dosage was reduced to 200 mg/day over a period of 10 days. Parallel to clozapine diminution, eosinophilia subsided and the pedal edema gradually diminished.

Comment
There have been reports of an association between clozapine and a host of general medical conditions. These include: de novo onset or exacerbation of preexisting diabetes mellitus, paradoxical hypertension, lactic acidosis with fatal myocardial failure, acute pancreatitis [1], and pheochromocytoma-like syndrome suggesting